Baxter International Inc (New York Stock Exchange:BAX)
| Market Cap | $13.14B+39.7% |
| Revenue (ttm) | $11.61B+5.3% |
| Net Income | -$723.00M-112.0% |
| EPS | -$1.38-109.2% |
| Shares Out | 517.35M |
| PE Ratio | n/a |
| Forward PE | 12.44 |
| Dividend | $0.04(0.16%) |
| Ex-Dividend Date | Nov 27, 2026 |
| Volume | 4,318,244 |
| Open | $25.43 |
| Previous Close | $25.39 |
| Day's Range | $25.25 - $26.07 |
| 52-Week Range | $15.73 - $30.00 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | $23.83(-6.14%) |
| Earnings Date | Feb 11, 2027 |
About BAX
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Analyst consensus
4 firms rating BAX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 27, 2026Ex-dividend date
- Feb 11, 2027Earnings report
$BAX stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of BAX by members of U.S. Congress
| Michael T. McCaulHouse / R | Purchase$15.00K – $50.00K | Mar 23, 2026 |
| Michael T. McCaulHouse / R | Purchase$50.00K – $100.00K | Jan 13, 2026 |
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Oct 31, 2025 |
| Lisa C. McClainHouse / R | Purchase$1.00K – $15.00K | Oct 30, 2025 |
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Oct 30, 2025 |
| Lisa C. McClainHouse / R | Purchase$1.00K – $15.00K | Sep 25, 2025 |
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Aug 4, 2025 |
| Lisa C. McClainHouse / R | Purchase$1.00K – $15.00K | Jul 22, 2025 |
Recently reported changes in BAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BAX Revenue by Segment or Geography
| Medical Products & Therapies | $2.10B | 72.28% |
| Healthcare Systems & Technologies | $806.00M | 27.72% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BAX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BAX
| VOOVanguard S&P 500 ETF | $316.17M |
| VTIVanguard Morningstar Total Stock Market ETF | $297.98M |
| VBVanguard Morningstar Small-Cap ETF | $266.57M |
| RSPInvesco S&P 500 Equal Weight ETF | $212.89M |
| IVViShares Core S&P 500 ETF | $176.84M |
| SPYState Street SPDR S&P 500 ETF | $161.00M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BAX’s recent data — informational, not investment advice
What’s Behind the Score
News check: One substantive BAX headline emphasizing long-term investment appeal; market report mentions BAX as competitor in gynecological equipment segment.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| PZLV | Pzena U.S. Large Cap Value ETF | 5.12% |
| ADPV | Adaptiv Select ETF | 3.97% |
| SCIU | Global X Scientific Beta US ETF | 2.70% |
| CVGD | CresAlta Global Dividend ETF | 2.30% |
| MDEV | First Trust Indxx Medical Devices ETF | 2.02% |
| IHI | iShares U.S. Medical Devices ETF | 1.68% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.60% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 1.58% |
| RYH | Invesco S&P 500 Equal Weight Health Care ETF | 1.58% |
| FPAG | FPA Global Equity ETF | 1.55% |
| BLCV | iShares Large Cap Value Active ETF | 1.24% |
| ZUH.TO | BMO Equal Weight US Health Care Hedged to CAD Index ETF | 1.08% |
Weight is the stock’s share of each fund’s holdings.
